StocksMedium•5 November 2026•
1 min read
Neuren Pharmaceuticals Raises 2026 Royalty Guidance on Strong DAYBUE Sales
Key Facts
1Neuren Pharmaceuticals raised its full-year 2026 royalty income guidance to between US$56 million and US$58 million.
2The company secured a US$35 million milestone payment from its partner Acadia Pharmaceuticals.
Neuren Pharmaceuticals raised its full-year 2026 royalty income guidance to between US$56 million and US$58 million. International Business Times Australia reported that the upgrade follows robust Q3 net sales of Daybue, a treatment for Rett syndrome, in the United States. Additionally, the company secured a US$35 million milestone payment from its partner Acadia Pharmaceuticals.
Acadia Pharmaceuticals (ACAD) closed at $21.47 on November 4, 2026, after trading between a day high of $21.54 and a low of $20.51. The guidance update reflects a 51% year-over-year increase in third-quarter royalty income, which reached $16.4 million, driven by the strong market uptake of Daybue.